Project Description
Esam Azhar, et.al
https://doi.org/10.1111/vox.13043
In a study published in VoxSanguinis , Esam Azhar et. al. confirmed the complete effectiveness of amotosalen/UVA light treatment to inactivate SARS-CoV-2 in human plasma toreduce the risk of potential transmission through blood transfusion. They inoculated a pool of three whole-blood-derived human plasma units (630–650 ml) with a clinical SARS-CoV-2 isolate. Spiked units were treatedwith amotosalen/UVA light (INTERCEPT Blood SystemTM) to inactivate SARS-CoV-2. Infectious titres and genomic viral load were assessed by plaque assayand real-time quantitative PCR. Inactivated samples were subjected to three successive passages on permissive tissue culture to exclude the presence of replication-competent viral particles. The meanlog reduction of >3.32 –/+ 0.2 . Passaging of inactivated samples on permissive tissue showed no viral replication even after 9 days of incubation and three passages, confirming complete inactivation.
